Expression of inhibitory regulators of innate immunity in patients with active tuberculosis

BMC Infectious Diseases

Volumn 15, Issue 1, 2015, Pages

  Blok, Dana C ^a   Kager, Liesbeth M ^a   Hoogendijk, Arie J ^a   Lede, Ivar O ^a   Rahman, Wahid ^c   Afroz, Rumana ^c   Bresser, Paul ^a,c   van der Zee, Jaring S ^a,c   Ghose, Aniruddha ^c   Visser, Caroline E ^a   de Jong, Menno D ^a   Zahed, Abu Shahed Md ^c   Husain, Md Anwar ^c   Alam, Khan Mashrequl ^c   Barua, Pravat Chandra ^d   Hassan, Mahtabuddin ^c   Hossain, Ahmed ^e   Tayab, Md Abu ^f   Lutter, Rene ^a,b   Day, Nick ^g   Dondorp, Arjen M ^g   de Vos, Alex F ^a   van 't Veer, Cornelis ^a   van der Poll, Tom ^a   more..

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

^c CHITTAGONG MEDICAL COLLEGE HOSPITAL   (Bangladesh)

^d National TB Control Programme   (Bangladesh)

^e Chest Disease Clinic Chittagong (CDCC)   (Bangladesh)

^f Chittagong General Hospital   (Bangladesh)

^g MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Bronchoscopy; Innate immunity; Lung inflammation; mycobacterium tuberculosis; Negative regulators of TLR signaling; Toll like receptors

Indexed keywords

INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 3; INTERLEUKIN 1 RECEPTOR LIKE 1; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 8; MESSENGER RNA; SUPPRESSOR OF CYTOKINE SIGNALING 3; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG; IL8 PROTEIN, HUMAN;

ADULT; ARTICLE; BANGLADESHI; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; INNATE IMMUNITY; LUNG ALVEOLUS MACROPHAGE; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN BLOOD LEVEL; ADOLESCENT; AGED; BANGLADESH; BLOOD; FLOW CYTOMETRY; IMMUNOLOGY; MIDDLE AGED; MONONUCLEAR CELL; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, PULMONARY; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BANGLADESH; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNITY, INNATE; INTERLEUKIN-8; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; TOLL-LIKE RECEPTORS; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

EID: 84928231190     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/s12879-015-0833-z     Document Type: Article

References (47)

1. Global Tuberculosis Report 2012. In Book Global Tuberculosis Report 2012 (Editor ed. eds.), WHO/HTM/TB/2012.6 edition. City: WHO; 2013.
2. Zumla A, Raviglione M, Hafner R, von Reyn CF. Tuberculosis. N Engl J Med. 2013;368:745-55.
3. Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity. 2011;34:637-50.
4. Kleinnijenhuis J, Oosting M, Joosten LA, Netea MG, Van Crevel R. Innate immune recognition of Mycobacterium tuberculosis. Clin Dev Immunol. 2011;2011:405310.
5. O'Garra A, Redford PS, McNab FW, Bloom CI, Wilkinson RJ, Berry MP. The immune response in tuberculosis. Annu Rev Immunol. 2013;31:475-527.
6. Korbel DS, Schneider BE, Schaible UE. Innate immunity in tuberculosis: myths and truth. Microbes Infect. 2008;10:995-1004.
7. Liew FY, Xu D, Brint EK, O'Neill LA. Negative regulation of toll-like receptor-mediated immune responses. Nat Rev Immunol. 2005;5:446-58.
8. Almeida AS, Lago PM, Boechat N, Huard RC, Lazzarini LC, Santos AR, et al. Tuberculosis is associated with a down-modulatory lung immune response that impairs Th1-type immunity. J Immunol. 2009;183:718-31.
9. Chang JS, Huggett JF, Dheda K, Kim LU, Zumla A, Rook GA. Myobacterium tuberculosis induces selective up-regulation of TLRs in the mononuclear leukocytes of patients with active pulmonary tuberculosis. J Immunol. 2006;176:3010-8.
10. Constantoulakis P, Filiou E, Rovina N, Chras G, Hamhougia A, Karabela S, et al. In vivo expression of innate immunity markers in patients with Mycobacterium tuberculosis infection. BMC Infect Dis. 2010;10:243.
11. Juarez E, Nunez C, Sada E, Ellner JJ, Schwander SK, Torres M. Differential expression of Toll-like receptors on human alveolar macrophages and autologous peripheral monocytes. Respir Res. 2010;11:2.
12. Milovanovic M, Volarevic V, Radosavljevic G, Jovanovic I, Pejnovic N, Arsenijevic N, et al. IL-33/ST2 axis in inflammation and immunopathology. Immunol Res. 2012;52:89-99.
13. National Guidelines and Operational manual for Tuberculosis Control. In Book National Guidelines and Operational manual for Tuberculosis Control (Editor ed.eds.). City: National Tuberculosis Control Programme, Directorate General of Health Services, Ministry of Health and Family Welfare; Dhaka, Bangladesh; 2012.
14. Hoogerwerf JJ, de Vos AF, Bresser P, van der Zee JS, Pater JM, de Boer A, et al. Lung inflammation induced by lipoteichoic acid or lipopolysaccharide in humans. Am J Respir Crit Care Med. 2008;178:34-41.
15. Ruijter JM, Ramakers C, Hoogaars WM, Karlen Y, Bakker O, van den Hoff MJ, et al. Amplification efficiency: linking baseline and bias in the analysis of quantitative PCR data. Nucleic Acids Res. 2009;37:e45.
16. Lodder EM, Scicluna BP, Milano A, Sun AY, Tang H, Remme CA, et al. Dissection of a quantitative trait locus for PR interval duration identifies Tnni3k as a novel modulator of cardiac conduction. PLoS Genet. 2012;8:e1003113.
17. van 't Veer C, van den Pangaart PS, van Zoelen MA, de Kruif M, Birjmohun RS, Stroes ES, et al. Induction of IRAK-M is associated with lipopolysaccharide tolerance in a human endotoxemia model. J Immunol. 2007;179:7110-20.
18. Lupberger J, Kreuzer KA, Baskaynak G, Peters UR, le Coutre P, Schmidt CA. Quantitative analysis of beta-actin, beta-2-microglobulin and porphobilinogen deaminase mRNA and their comparison as control transcripts for RT-PCR. Mol Cell Probes. 2002;16:25-30.
19. Brint EK, Xu D, Liu H, Dunne A, McKenzie AN, O'Neill LA, et al. ST2 is an inhibitor of interleukin 1 receptor and Toll-like receptor 4 signaling and maintains endotoxin tolerance. Nat Immunol. 2004;5:373-9.
20. Wald D, Qin J, Zhao Z, Qian Y, Naramura M, Tian L, et al. SIGIRR, a negative regulator of Toll-like receptor-interleukin 1 receptor signaling. Nat Immunol. 2003;4:920-7.
21. Walzl G, Ronacher K, Hanekom W, Scriba TJ, Zumla A. Immunological biomarkers of tuberculosis. Nat Rev Immunol. 2011;11:343-54.
22. Hawn TR, Misch EA, Dunstan SJ, Thwaites GE, Lan NT, Quy HT, et al. A common human TLR1 polymorphism regulates the innate immune response to lipopeptides. Eur J Immunol. 2007;37:2280-9.
23. Etokebe GE, Skjeldal F, Nilsen N, Rodionov D, Knezevic J, Bulat-Kardum L, et al. Toll-like receptor 2 (P631H) mutant impairs membrane internalization and is a dominant negative allele. Scand J Immunol. 2010;71:369-81.
24. Texereau J, Chiche JD, Taylor W, Choukroun G, Comba B, Mira JP. The importance of Toll-like receptor 2 polymorphisms in severe infections. Clin Infect Dis. 2005;41 Suppl 7:S408-15.
25. Maartens G, Wilkinson RJ. Tuberculosis. Lancet. 2007;370:2030-43.
26. Khor CC, Chapman SJ, Vannberg FO, Dunne A, Murphy C, Ling EY, et al. A Mal functional variant is associated with protection against invasive pneumococcal disease, bacteremia, malaria and tuberculosis. Nat Genet. 2007;39:523-8.
27. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005;23:479-90.
28. Kuroiwa K, Arai T, Okazaki H, Minota S, Tominaga S. Identification of human ST2 protein in the sera of patients with autoimmune diseases. Biochem Biophys Res Commun. 2001;284:1104-8.
29. Oshikawa K, Yanagisawa K, Tominaga S, Sugiyama Y. ST2 protein induced by inflammatory stimuli can modulate acute lung inflammation. Biochem Biophys Res Commun. 2002;299:18-24.
30. Bhardwaj A, Januzzi Jr JL. ST2: a novel biomarker for heart failure. Expert Rev Mol Diagn. 2010;10:459-64.
31. Hoogerwerf JJ, Tanck MW, van Zoelen MA, Wittebole X, Laterre PF, van der Poll T. Soluble ST2 plasma concentrations predict mortality in severe sepsis. Intensive Care Med. 2010;36:630-7.
32. Wagenaar JF, Gasem MH, Goris MG, Leeflang M, Hartskeerl RA, van der Poll T, et al. Soluble ST2 levels are associated with bleeding in patients with severe Leptospirosis. PLoS Negl Trop Dis. 2009;3:e453.
33. Wieland CW, van der Windt GJ, Florquin S, McKenzie AN, van der Poll T. ST2 deficient mice display a normal host defense against pulmonary infection with Mycobacterium tuberculosis. Microbes Infect. 2009;11:524-30.
34. Pavan Kumar N, Anuradha R, Andrade BB, Suresh N, Ganesh R, Shankar J, et al. Circulating biomarkers of pulmonary and extrapulmonary tuberculosis in children. Clin Vaccine Immunol. 2013;20:704-11.
35. Dimitriou ID, Clemenza L, Scotter AJ, Chen G, Guerra FM, Rottapel R. Putting out the fire: coordinated suppression of the innate and adaptive immune systems by SOCS1 and SOCS3 proteins. Immunol Rev. 2008;224:265-83.
36. Masood KI, Rottenberg ME, Carow B, Rao N, Ashraf M, Hussain R, et al. SOCS1 gene expression is increased in severe pulmonary tuberculosis. Scand J Immunol. 2012;76:398-404.
37. Masood KI, Rottenberg ME, Salahuddin N, Irfan M, Rao N, Carow B, et al. Expression of M. tuberculosis-induced suppressor of cytokine signaling (SOCS) 1, SOCS3, FoxP3 and secretion of IL-6 associates with differing clinical severity of tuberculosis. BMC Infect Dis. 2013;13:13.
38. Mistry R, Cliff JM, Clayton CL, Beyers N, Mohamed YS, Wilson PA, et al. Gene-expression patterns in whole blood identify subjects at risk for recurrent tuberculosis. J Infect Dis. 2007;195:357-65.
39. Carow B, Reuschl AK, Gavier-Widen D, Jenkins BJ, Ernst M, Yoshimura A, et al. Critical and independent role for SOCS3 in either myeloid or T cells in resistance to Mycobacterium tuberculosis. PLoS Pathog. 2013;9:e1003442.
40. Pathak SK, Basu S, Bhattacharyya A, Pathak S, Kundu M, Basu J. Mycobacterium tuberculosis lipoarabinomannan-mediated IRAK-M induction negatively regulates Toll-like receptor-dependent interleukin-12 p40 production in macrophages. J Biol Chem. 2005;280:42794-800.
41. Burns K, Clatworthy J, Martin L, Martinon F, Plumpton C, Maschera B, et al. Tollip, a new component of the IL-1RI pathway, links IRAK to the IL-1 receptor. Nat Cell Biol. 2000;2:346-51.
42. Zhang G, Ghosh S. Negative regulation of toll-like receptor-mediated signaling by Tollip. J Biol Chem. 2002;277:7059-65.
43. Shah JA, Vary JC, Chau TT, Bang ND, Yen NT, Farrar JJ, et al. Human TOLLIP regulates TLR2 and TLR4 signaling and its polymorphisms are associated with susceptibility to tuberculosis. J Immunol. 2012;189:1737-46.
44. Li L, Chen SF, Liu Y. MAP kinase phosphatase-1, a critical negative regulator of the innate immune response. Int J Clin Exp Med. 2009;2:48-67.
45. Cheung BK, Yim HC, Lee NC, Lau AS. A novel anti-mycobacterial function of mitogen-activated protein kinase phosphatase-1. BMC Immunol. 2009;10:64.
46. Kelly C, Shields MD, Elborn JS, Schock BC. A20 regulation of nuclear factor-kappaB: perspectives for inflammatory lung disease. Am J Respir Cell Mol Biol. 2011;44:743-8.
47. Garlanda C, Di Liberto D, Vecchi A, La Manna MP, Buracchi C, Caccamo N, et al. Damping excessive inflammation and tissue damage in Mycobacterium tuberculosis infection by Toll IL-1 receptor 8/single Ig IL-1-related receptor, a negative regulator of IL-1/TLR signaling. J Immunol. 2007;179:3119-25.